Efficacy and safety of QGE031 versus placebo and Omalizumab in patients aged 18-75 years with asthma Responder rate compared to placebo

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Safety and efficacy of BEZ235 in patients with pancreatic neuroendocrine tumors (pNET) To estimate the efficacy of BEZ235 in adult patients with advanced (unresectable or metastatic) pNET (PFS)

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A twelve week, randomized, double-blind, parallel-group multicentre study to evaluate the efficacy and safety of the combination of aliskiren/ramipril/amlodipine (300/10/10mg), compared to the combinations of ramipril/amlodipine (10/10mg) and aliskiren/amlodipine (300/10mg) in patients with essential hypertension and metabolic syndrome not adequately responsive to amlodipine 10mg The primary objectives of this study are: 1. To demonstrate that the combination of aliskiren / ramipril / amlodipine (300/10/10 mg) has superior efficacy compared to the combinations of ramipril / am...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, double-blind, parallel-group, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the renoprotective effect of renin inhibition with Aliskiren as an alternative to irbesartan in Type 2 patients with incipient/overt diabetic nephropathy • To investigate whether renin-inhibition using Aliskiren 300 mg daily could be a treatment alternative to the angiotensin II receptor antagonist Irbesartan 300 mg with an equivalent potential for re...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 12 week treatment, open-label, multicenter study to investigate the efficacy and safety of valsartan 160-320 mg with regard to effects on lipid subfractions in hypertensive patients with metabolic syndrome To demonstrate that valsartan 320 mg has a positive effect on small, dense LDL subfractions (LDL 5+6) in hypertensive patients with metabolic syndrome after 12 weeks of treatment.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to assess the effect of 3 different doses of LIK066 in patients with type 2 diabetes and heart failure, compared to the effect of placebo or empagliflozin To assess the dose-response relationship of three dose regimens of LIK066 as measured by the change from baseline in NT-proBNP relative to placebo after 12 weeks of treatment in T2DM patients with HF

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Multicenter randomized open-label three-arms controlled 12 months clinical proof of concept study to evaluate efficacy and safety of Ranibizumab alone or in combination with laser treatment vs. laser treatment alone in Proliferative Diabetic Retinopathy Change of area of neovascularizations as measured by Fluorescein Angiography at month 12 (difference to baseline value).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

The study is to gather evidence of LFG316 efficacy in treatment of transplant associated microangiopathy (TAM) after hematopoetic precursor cell transplantation To assess the hematological response rate in patients with TAM receiving LFG316 compared to standard of care (SoC)

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An uncontrolled, multicenter 12 month long term study on skin reconstitution with Elidel® (pimecrolimus) 1% cream in adult patients with atopic eczema and corticosteroid induced skin damage To investigate the reconstitution of steroid damaged skin with pimecrolimus 1% cream by the decrease of the Dermatophot® score from baseline to end of the study.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to allow access to imatinib for patients who are on imatinib treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator To evaluate long term safety data (SAEs and AEs).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune